Table 4. Characteristics, clinical outcomes and platelet aggregation between patients receiving clopidogrel plus aspirin and patients receiving clopidogrel alone.
| clopidogrel alone (n = 144) | clopidogrel plus aspirin (n = 231) | p value | |
|---|---|---|---|
| Age (years) | 69.4 ± 10.8 | 68.7 ± 12.6 | 0.273 |
| Male (n, %) | 91 (63.2) | 151 (65.4) | 0.708 |
| Hypertension (n, %) | 115 (79.9) | 178 (77.1) | 0.512 |
| Diabetes mellitus (n, %) | 55 (38.2) | 102 (44.2) | 0.279 |
| Current smoker (n, %) | 60 (41.7) | 98 (42.4) | 0.992 |
| Previous MI (n, %) | 6 (4.2) | 12 (5.2) | 0.665 |
| Hyperlipidemia (n, %) | 100 (69.4) | 162 (70.1) | 0.989 |
| Fasting blood glucose (mmol/L) | 7.1 ± 2.6 | 7.3 ± 2.7 | 0.364 |
| Hemoglobin A1c (%) | 7.0 ± 1.7 | 7.1 ± 2.2 | 0.612 |
| Admission NIHSS | 6.1 ±1.8 | 5.9 ± 1.9 | 0.304 |
| Stroke subtype | |||
| Atherothrombotic (n, %) | 82 (56.9) | 149 (64.5) | 0.152 |
| Small artery disease (n, %) | 62 (43.1) | 82 (35.5) | 0.152 |
| In-hospital treatment (n, %) | |||
| Antihypertensive drugs | 122 (84.7) | 200 (86.6) | 0.621 |
| Hypoglycemic drugs | 72 (50.0) | 124 (53.7) | 0.482 |
| Statins | 141 (97.9) | 228 (98.7) | 0.991 |
| END (n, %) | 45 (31.3) | 50 (21.6) | 0.041 |
| RIS (n, %) | 1 (0.7) | 2 (0.9) | 0.982 |
| MI (n, %) | 0 (0.0) | 1 (0.4) | 0.432 |
| Death (n, %) | 1 (0.7) | 1 (0.5) | 0.723 |
| Safety outcomes | |||
| Asymptomatic HT (n, %) | 2 (1.4) | 5 (2.2) | 0.342 |
| Asymptomatic ICH (n, %) | 1(0.7) | 1 (0.5) | 0.723 |
| Extracranialbleeding (n, %) | 3 (2.1) | 8 (3.5) | 0.424 |
| AA-induced platelet aggregation (%) | |||
| before clopidogrel | 75.2 ± 16.9 | 76.1 ± 19.3 | 0.643 |
| after 7–10 days clopidogrel | 46.9 ± 12.4 | 27.2 ± 9.6 | <0.001 |
| inhibition | 27.7 ± 9.6 | 49.2 ±12.3 | <0.001 |
| ADP-induced platelet aggregation (%) | |||
| before clopidogrel | 73.2 ± 16.7 | 72.1 ± 17.6 | 0.522 |
| after 7–10 days clopidogrel | 32.7 ± 11.8 | 31.8 ± 9.8 | 0.442 |
| inhibition | 39.9 ± 10.9 | 41.3 ± 11.6 | 0.871 |
MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; END, early neurological deterioration; RIS, recurrent ischemic stroke; MI, myocardial infarction; HT, hemorrhagic transformation; ICH, intracranial hemorrhage; AA, arachidonic acid; ADP, adenosine diphosphate.